Advertisement
Screener

IGC PHARMA, INC. (IGC) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

IGC PHARMA, INC. Comprehensive Income

IGC PHARMA, INC. (IGC) reported Comprehensive Income of -$2.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14

  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$2.93M.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$2.41M.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$744.00K.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$1.84M.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$7.15M.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$13.03M.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$11.93M.
  • IGC PHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$15.21M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30-$2.93M
10-Q · filed 2026-08-14
-$5.34M
10-Q · filed 2026-08-14
-$6.09M
derived: sum of 3 quarters · filed 2026-08-14
-$7.93M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$2.41M
10-Q · filed 2026-05-15
-$3.15M
derived: sum of 2 quarters · filed 2026-05-15
-$4.99M
derived: sum of 3 quarters · filed 2026-05-15
-$6.60M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$744.00K
derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18
-$2.58M
derived: sum of 2 quarters · filed 2026-03-18
-$4.19M
10-KT · filed 2026-03-18
-$5.38M
derived: sum of 4 quarters · filed 2026-08-14
2025-09-30-$1.84M
10-Q · filed 2025-11-14
-$3.44M
10-Q · filed 2025-11-14
-$4.63M
derived: sum of 3 quarters · filed 2026-08-14
-$6.48M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$1.60M
10-Q · filed 2026-08-14
-$2.79M
10-Q · filed 2026-08-14
-$4.64M
derived: sum of 3 quarters · filed 2026-08-14
-$6.37M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$1.19M
10-Q · filed 2026-05-15
-$3.04M
derived: sum of 2 quarters · filed 2026-05-15
-$4.77M
derived: sum of 3 quarters · filed 2026-05-15
-$7.15M
10-KT · filed 2026-03-18
2024-12-31-$1.85M
10-Q · filed 2025-02-14
-$3.58M
derived: sum of 2 quarters · filed 2025-11-14
-$5.96M
10-KT · filed 2026-03-18
-$8.84M
derived: sum of 4 quarters · filed 2025-11-14
2024-09-30-$1.73M
10-Q · filed 2025-11-14
-$4.11M
10-Q · filed 2025-11-14
-$7.00M
derived: sum of 3 quarters · filed 2025-11-14
-$12.57M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$2.38M
10-Q · filed 2025-08-14
-$5.26M
derived: sum of 2 quarters · filed 2025-08-14
-$10.84M
derived: sum of 3 quarters · filed 2025-08-14
-$13.35M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$2.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-27
-$8.45M
derived: sum of 2 quarters · filed 2025-06-27
-$10.97M
derived: sum of 3 quarters · filed 2025-06-27
-$13.03M
10-K · filed 2025-06-27
2023-12-31-$5.57M
10-Q · filed 2025-02-14
-$8.09M
derived: sum of 2 quarters · filed 2025-02-14
-$10.15M
10-Q · filed 2025-02-14
-$14.14M
derived: sum of 4 quarters · filed 2025-02-14
2023-09-30-$2.51M
10-Q · filed 2024-11-12
-$4.58M
10-Q · filed 2024-11-12
-$8.57M
derived: sum of 3 quarters · filed 2024-11-12
-$10.88M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$2.07M
10-Q · filed 2024-08-07
-$6.05M
derived: sum of 2 quarters · filed 2024-08-07
-$8.37M
derived: sum of 3 quarters · filed 2024-08-07
-$10.99M
derived: sum of 4 quarters · filed 2024-08-07
2023-03-31-$3.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-24
-$6.30M
derived: sum of 2 quarters · filed 2024-06-24
-$8.92M
derived: sum of 3 quarters · filed 2024-06-24
-$11.93M
10-K · filed 2024-06-24
2022-12-31-$2.31M
10-Q · filed 2024-02-14
-$4.93M
derived: sum of 2 quarters · filed 2024-02-14
-$7.94M
10-Q · filed 2024-02-14
-$14.65M
derived: sum of 4 quarters · filed 2024-02-14
2022-09-30-$2.62M
10-Q · filed 2023-11-09
-$5.63M
10-Q · filed 2023-11-09
-$12.34M
derived: sum of 3 quarters · filed 2023-11-09
-$14.64M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$3.00M
10-Q · filed 2023-08-10
-$9.71M
derived: sum of 2 quarters · filed 2023-08-10
-$12.02M
derived: sum of 3 quarters · filed 2023-08-10
-$16.34M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$6.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-07
-$9.01M
derived: sum of 2 quarters · filed 2023-07-07
-$13.34M
derived: sum of 3 quarters · filed 2023-07-07
-$15.21M
10-K · filed 2023-07-07
2021-12-31-$2.30M
10-Q · filed 2023-02-14
-$6.63M
derived: sum of 2 quarters · filed 2023-02-14
-$8.50M
10-Q · filed 2023-02-14
-$11.50M
derived: sum of 4 quarters · filed 2023-02-14
2021-09-30-$4.32M
10-Q · filed 2022-11-01
-$6.20M
10-Q · filed 2022-11-01
-$9.20M
derived: sum of 3 quarters · filed 2022-11-01
-$11.48M
derived: sum of 4 quarters · filed 2022-11-01
2021-06-30-$1.87M
10-Q · filed 2022-08-05
-$4.87M
derived: sum of 2 quarters · filed 2022-08-05
-$7.15M
derived: sum of 3 quarters · filed 2022-08-05
-$8.67M
derived: sum of 4 quarters · filed 2022-08-05
2021-03-31-$3.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23
-$5.28M
derived: sum of 2 quarters · filed 2022-06-23
-$6.79M
derived: sum of 3 quarters · filed 2022-06-23
-$8.73M
10-K · filed 2022-06-23
2020-12-31-$2.28M
10-Q · filed 2022-02-10
-$3.80M
derived: sum of 2 quarters · filed 2022-02-10
-$5.74M
10-Q · filed 2022-02-10
-$9.16M
derived: sum of 4 quarters · filed 2022-02-10
2020-09-30-$1.51M
10-Q · filed 2021-10-29
-$3.46M
10-Q · filed 2021-10-29
-$6.87M
derived: sum of 3 quarters · filed 2021-10-29
-$8.52M
derived: sum of 4 quarters · filed 2021-10-29
2020-06-30-$1.94M
10-Q · filed 2021-08-11
-$5.36M
derived: sum of 2 quarters · filed 2021-08-11
-$7.00M
derived: sum of 3 quarters · filed 2021-08-11
-$8.33M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31-$3.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14
-$5.06M
derived: sum of 2 quarters · filed 2021-06-14
-$6.39M
derived: sum of 3 quarters · filed 2021-06-14
-$7.75M
10-K · filed 2021-06-14
2019-12-31-$1.65M
10-Q · filed 2021-02-16
-$2.97M
derived: sum of 2 quarters · filed 2021-02-16
-$4.33M
10-Q · filed 2021-02-16
-$5.87M
derived: sum of 4 quarters · filed 2021-02-16
2019-09-30-$1.32M
10-Q · filed 2020-11-20
-$2.68M
10-Q · filed 2020-11-20
-$4.22M
derived: sum of 3 quarters · filed 2020-11-20
-$5.13M
derived: sum of 4 quarters · filed 2020-11-20
2019-06-30-$1.36M
10-Q · filed 2020-08-19
-$2.90M
derived: sum of 2 quarters · filed 2020-08-19
-$3.81M
derived: sum of 3 quarters · filed 2020-08-19
-$5.00M
derived: sum of 4 quarters · filed 2020-08-19
2019-03-31-$1.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-13
-$2.45M
derived: sum of 2 quarters · filed 2020-07-13
-$3.64M
derived: sum of 3 quarters · filed 2020-07-13
-$4.46M
10-K · filed 2020-07-13
2018-12-31-$909.00K
10-Q · filed 2020-02-10
-$2.10M
derived: sum of 2 quarters · filed 2020-02-10
-$2.92M
10-Q · filed 2020-02-10
2018-09-30-$1.19M
10-Q · filed 2019-11-06
-$2.01M
10-Q · filed 2019-11-06
2018-06-30-$819.00K
10-Q · filed 2019-08-09
2018-03-31-$1.79M
10-K · filed 2019-06-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
NextCure, Inc. (NXTC)United States$0.024B-0.15